Moderna's COVID Forecast for 2023 Remains Promising, Analysts Reveal

Analysts believe that Moderna is likely to meet its sales target for this year as it only needs to tap a small portion of the private market with its COVID-19 vaccine. Around 20 million people need to be vaccinated with Moderna's updated vaccine for the company to reach $2 billion in 2023 sales from the private market. Moderna's sales forecast for its COVID-19 vaccine has been called into question after Pfizer lowered its outlook due to lower-than-expected vaccination rates. However, analysts expect Moderna to avoid a similar decline in sales outlook as it started off more conservative. Moderna's shares have fallen by 22% since Pfizer's warning. The company's broader mRNA-based respiratory pipeline, including flu and RSV vaccines, is expected to reach $10 billion to $12 billion in sales by 2025.